Q2 figures remain small in absolute terms and do not change our view of the case. More importantly, Intervacc has taken several steps forward, including the application for a 12-month duration of immunity and continued progress towards the US market. We lower our base case slightly to SEK1.9 (2.0).
LÄS MER
